News | January 28, 2023
Aarti Drugs Q3 FY23 revenue grows 4%
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
The company will not receive any proceeds from the offer as all of it will go to the promoter selling shareholder.
Dr. Reddy’s will manufacture the Active Pharmaceutical Ingredient and finished drug at its facilities approved by USFDA
This will give either party customers access enzyme expertise and assets, resulting in cost-effective, green processing for API manufacturing.
Surana is a chartered accountant with an all-India rank.
China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production
The company will submit an action plan on the observations and will engage with US FDA for next steps.
Soluplus branded excipient play a critical role in enabling the drug development process for poorly soluble active pharmaceutical ingredients
The Business Undertaking of Watson is engaged in the business of developing, manufacturing, marketing and sale of API.
This will enable the company to consume 100% of the solar energy to be supplied by Ethan Energy India Private Limited from their 10 MW Solar Energy plant
Subscribe To Our Newsletter & Stay Updated
